Problem with Sun Pharma may aggravate: Surajit Pal

Sun Pharma has got 11 observations from US-FDA for their Dadra unit.

In an interview to CNBC-TV18, Surajit Pal of Prabhudas Lilladher shared his views on the latest happenings in the pharmaceutical sector.

"The problem with Sun Pharma will aggravate. 11 observations is not a good idea", he said.

At the moment, Glenmark Pharma, Aurobindo Pharma and Thyrocare are his buy calls in the pharma space.